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AbsTRACT
Rapid advances in technologies in the field of genomics 
such as high throughput DNA sequencing, big data 
processing by machine learning algorithms and gene- 
editing techniques are expected to make precision 
medicine and gene- therapy a greater reality. However, 
this development will raise many important new issues, 
including ethical, moral, social and privacy issues. 
The field of exercise genomics has also advanced by 
incorporating these innovative technologies. There is 
therefore an urgent need for guiding references for 
sport and exercise genomics to allow the necessary 
advancements in this field of sport and exercise 
medicine, while protecting athletes from any invasion 
of privacy and misuse of their genomic information. 
Here, we update a previous consensus and develop a 
guiding reference for sport and exercise genomics based 
on a SWOT (Strengths, Weaknesses, Opportunities and 
Threats) analysis. This SWOT analysis and the developed 
guiding reference highlight the need for scientists/
clinicians to be well- versed in ethics and data protection 
policy to advance sport and exercise genomics without 
compromising the privacy of athletes and the efforts of 
international sports federations. Conducting research 
based on the present guiding reference will mitigate to a 
great extent the risks brought about by inappropriate use 
of genomic information and allow further development 
of sport and exercise genomics in accordance with best 
ethical standards and international data protection 
principles and policies. This guiding reference should 
regularly be updated on the basis of new information 
emerging from the area of sport and exercise medicine 
as well as from the developments and challenges in 
genomics of health and disease in general in order to 
best protect the athletes, patients and all other relevant 
stakeholders.
InTRoduCTIon
Recent advances in DNA sequencing technology 
enable the analysis of a large number of genomes1—a 
genome is a complete set of DNA, including all the 
genes of an organism. The generation of large data 
combined with new and improved methods of anal-
ysis, which includes machine learning and artificial 
intelligence, is collectively predicted to advance 
precision medicine considerably to facilitate optimal 
tailored medical therapies for the individual based 
on the individuals complete clinical and risk profiles 
which includes their l genomic information. This new 
reality has the potential to revolutionise healthcare 
by substantially enhancing the efficacy of treatment 
with a promise to significantly reduce the costs asso-
ciated with healthcare provision.2 To achieve the 
necessary progress in precision medicine, many coun-
tries have established large scale biobanks and are 
performing analyses on large datasets (table 1).3 For 
example, the UK Biobank (2006–2010) has already 
genotyped approximately 500 000 participants using 
the UK BiLEVE Axiom Array and the UK Biobank 
Axiom Array and performed genome- wide associ-
ation studies (GWASs) in the largest to date single 
population- based cohort involving more than 20 000 
traits.4 5 The 100 000 Genomes Project, launched in 
the UK in 2012, is the first national whole- genome 
sequencing project targeting National Health Service 
(NHS) patients to complete the sequencing of 
100 000 whole genomes.6
These rapid advances in DNA sequencing tech-
nology have also introduced many new ethical 
and confidentiality issues such as reidentification 
of anonymised genotype data,7 data ownership,8 
newborn screening9 and incidental findings.10 These 
advances and the anticipation of a true revolution in 
precision medicine have created a lively market for 
direct to consumer (DTC) genetic testing compa-
nies.11 At present, the vast majority of company 
claims are more in line with future aspiration and 
promise rather than current evidence- based reality. 
Most DTC companies are too small to have any 
significant research and development (R&D) and 
therefore are solely dependent on the scientific 
community to generate new and clinically relevant 
data. There are also no guarantees that these compa-
nies will be allowed to freely exploit the data that 
will emerge due to patient confidentiality and data 
protection issues. It is likely that elaborate algorithms 
will be developed using big data processing methods 
and controlled by the larger companies that have the 
R&D resources to invest in the necessary analytical 
technology such as supercomputers, programmers 
and specialist bioinformaticians. At present, DNA 
sequencing technologies are able to generate data at 
a much faster rate than our ability to interpret and 
therefore appropriately exploit these data.
In addition to DNA sequencing technologies, 
gene- editing technology has also made significant 
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Table 1 Current large biobanks with populations over 100 000 individuals
biobank Cohort size Phenotyping data Genotyping platform References
Million Veteran Program 550 000 (400,000 genotyped) 
with goal for 1 million 
individuals
Baseline survey data, EHR structured data Affymetrix Axiom Biobank Gaziano, 2016122
All of Us Goal for 1 million individuals Baseline physical examination, baseline 
survey data, sensor based observations 
(wearable devices), EHR structured data, 
social media
Not yet determined, whole 
genome sequencing likely to factor 
prominently from outset
Precision Medicine Working Group, 2015123
UK BioBank 502 632 genotyped Web- based questionnaires, sensor based 
observations (wearable devices), EHR 
structured data
UK BiLEVE, UK Biobank Axiom http://www.ukbiobank.ac.uk/
Kaiser: Research Program 
on Genes, Environment, and 
Health
257 686 (176 200 genotyped), 
with goal for 500 000 individuals
Baseline survey data, EHR structured data Affymetrix Axiom Genome- Wide 
EUR Array
https://researchbank.kaiserpermanente.org/
Geisinger Health System 
MyCode Community Health 
Initiative
145 165 (92 455 genotyped) EHR structured data Illumina HumanExome array V1.1 Carey, 2016124
Vanderbilt: BioVU 225 000 genotyped EHR structured data Illumina Exome BeadChip, Illumina 
MEGA BeadChip
https://victr.vanderbilt.edu/pub/biovu/
China: Kadoorie Biobank >500 000 (32 000 genotyped) Baseline survey data, baseline physical exam, 
health insurance information
Affymetrix Axiom Biobank http://www.ckbiobank.org/
Japan Biobank 200 000 genotyped Baseline survey data, Annual review of 
incident disease
Multiple https://biobankjp.org/
National Biobank of Korea 525 416 (genotyped number 
unclear)
Repeated surveys and exams Not described Cho, 2012125
deCode 160 000 genotyped Geneologies, EHR structured data Illumina Omni-1 Quad BeadChips https://www.decode.com/
Finngen Goal for 500 000 individuals EHR structured data Not described https://www.finngen.fi/
This table was cited from Small et al.3
EHR, electronic health record.
advancements in recent years. In particular, clustered regu-
larly interspaced short palindromic repeats (CRISPR) together 
with CRISPR- associated proteins (eg, Cas9, CasX, Cas12a and 
Cas13), known as CRISPR/Cas systems are poised to make 
gene- editing truly revolutionary by enabling easy, rapid and 
cost effective editing of DNA sequences.12–15 Since inception 
in 199316 CRISPR technology has now advanced to the point 
of smart technology gels for drug delivery.17 This pioneering 
approach, particularly CRISPR/Cas9, is already being used to 
develop lifesaving/altering gene therapy in monogenic diseases 
such as sickle cell disease,18 Huntington’s disease,19 cystic 
fibrosis20 and Duchenne muscular dystrophy21 and poised to 
make big advances in the near future also in cancer treatment22 
This promising and effective tool also allows the editing of DNA 
sequences of human germlines.23 24 CRISPR, however, is not 
without limitations. For example, insertion- deletions (INDELS) 
delivered through CRISPR/Cas9 mechanism have been shown to 
induce foreign mRNA or proteins in approximately 50% of cell 
lines through ribosomal entry, thereby causing mutations and 
reduced production of viable genes.25 While gene- editing tools 
in human germline have been restricted to research and prohib-
ited in human reproduction by all countries that have estab-
lished gene editing regulations, CRISPR/Cas9 gene- editing was 
recently used for reproductive purposes with claims of gener-
ating the first gene- edited babies.26 This was a direct breach of 
Chinese law and led to a joint statement of 122 Chinese scien-
tists calling for urgent legislation against further ‘direct human 
experimentation’.27 There is therefore an urgent need to create 
the necessary regulatory framework to safeguard against the real 
threat of ‘genetic pollution’ of the human gene pool, a contro-
versial term to describe the process of intentional, uncontrolled 
and potentially unlawful, introduction of genetic material for the 
purpose of increasing the ‘fitness’ of a population or subsample 
of a population.28
In the field of sport and exercise sciences and medi-
cine, dissecting the relationship between genetic factors and 
health- related fitness, athletic performance, trainability and 
susceptibility for exercise- related health risks (eg, musculo-
skeletal injury) were previously attempted. Identification of 
specific sport and exercise- related genes are expected to be used 
for precision sports medicine to provide tailor- made training 
as well as to select optimal sports and/or other exercise activ-
ities for each individual. However, from previous candidate 
gene approaches and GWAS, there are very limited outcomes 
with clinical utility, and therefore a paradigm shift in sports 
genomics is urgently needed.29–33 However, with the exception 
of the Genetic- Biological Physical Activity Consortium (GenBi-
oPAC),30 which is aimed at understanding genetic and other 
biological factors in the regulation of physical activity, there are 
no significant funded international consortia to meet this aim. 
Progress towards such a significant development in the field of 
sport and exercise genomics will require a paradigm shift in line 
with recent recommendations for international collaborations 
such as the Athlome Project Consortium (see www. athlomecon-
sortium. org) which was launched in 2015 for the advancement 
of ‘omics’ in exercise sciences and medicine.31 The Athlome 
Consortium aims to collectively study the genotype and pheno-
type data currently available on elite athletes, in adaptation to 
exercise training and on exercise- related musculoskeletal inju-
ries both from individual studies and from consortia worldwide. 
One of the consortium projects, the 1000 Athlomes Project, aims 
to sequence 1000 genomes of sprinters and distance runners of 
West and East African descent to clarify the genetic architec-
ture of extreme athletic performance. To date, 72 world class 
Ethiopian and Kenyan distance runners have been sequenced 
and their genotype distribution has been compared with that 
of region- matched general population from the 1000 Genomes 
Project.31 34
As in other biomedical fields, large- scale genomic research 
is helping develop sport and exercise science and medicine in 
realising goals towards precision sports medicine and exercise 
prescription. Terms such as individualised response, personalised 
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medicine, stratified medicine, personalised prescription are 
increasingly being used as primarily inspirational concepts rather 
than current realities in terms of genomic technologies. Ross et 
al recently reported large interindividual differences in cardiore-
spiratory fitness (CRF) in response to standardised exercise and 
introduced measures to identify determinants and modifiers of 
CRF response.32 However, these necessary advances also intro-
duce many ethical problems that would be an obstacle to achieve 
precision sports medicine, particularly in terms of ethical and 
data protection issues. Given the rapid advances in gene- editing 
technology such as CRISPR/Cas9, and the fact that gene- edited 
babies are now a reality,23 24 gene doping or creating talented 
sports children by using gene- editing technique combined with 
the knowledge of sport and exercise genomics would be real-
istic in the very near future, however currently immature at this 
stage. Therefore, advances in human genomics if left completely 
unregulated would inevitably become a ‘weapon’ that would 
threaten the health and well- being of athletes and the general 
worldwide population.
Considering the rapid changes in circumstances surrounding 
genomic research and the threats described above, ethics and 
data protection policies (eg, GDPR/Data Protection Act 2018 in 
the UK and EU) should continuously be updated. As the first 
sequencing studies of elite athletes are being conducted,31 34 
there is an urgent need for a guiding reference for sport and 
exercise genomics to allow the necessary advancement in sports 
genomics while also protecting athletes from any invasion of 
privacy and misuse of their genomic data. This reference guide 
attempted here is presented as a SWOT (Strengths, Weaknesses, 
Opportunities and Threats) analysis. This guiding reference will 
be regularly updated, based on new and emerging evidence, 
from the area of sport and exercise medicine and from valuable 
lessons being learnt from the developments and challenges in 
genomics of health and disease in general.35 36
sWoT AnAlysIs
strengths
Previous twin and familial studies suggest that there is moderate 
heritability of ‘sport and exercise- related traits’ (eg, athletic 
performance, response to exercise training and fitness level).37–40 
Identification of genetic variants determining variabilities in 
sport and exercise- related traits may offer significant benefits to 
athletes and the general population. For example, the Heritage 
Family Study demonstrated a considerable heterogeneity in the 
change in maximal oxygen uptake (VO2max) in response to a 
20 week standardised exercise training programme (the range 
in training response: –114 to 1097 mL/min).32 37 Similarly, large 
individual variabilities in response to resistance training,41 and 
high- intensity interval training were also reported.42 Collec-
tively, evidence from human twin and family studies suggest that 
there are considerable interindividual differences in the response 
of CRF and other cardiometabolic traits to a given dose of exer-
cise, and are partly dependent on genetic factors.32 If the genetic 
variants that predict which type of exercise training is the most 
effective for each person are identified, then individualised ther-
apeutic exercise programme can be used in early intervention 
and chronic disease prevention.
From the perspective of athletes, musculoskeletal injuries 
such as soft tissue disruption (eg, Achilles tendon injury, ante-
rior cruciate ligament ruptures and shoulder dislocations), 
muscle strain, and stress fracture are serious medical condi-
tions that inhibit regular training and may shorten an athlete’s 
career. As genetic factors have been suggested to contribute to 
the susceptibility of musculoskeletal injuries,43 identification of 
musculoskeletal injury- related genetic loci may provide informa-
tion required to optimise training load that is tailored for training 
volume and intensity. Previous candidate gene approaches have 
demonstrated that several single nucleotide polymorphisms 
(SNPs) were associated with soft tissue ruptures,44–46 muscle 
strain47 48 and stress fracture.49 50 However, these SNPs have 
no current clinical utility because they have been replicated in 
limited independent populations. Functional analysis of these 
SNPs is, however, needed to achieve a greater understanding of 
the mechanisms of susceptibility to musculoskeletal injuries.
Genetic variants associated with elite athlete status in various 
sporting disciplines may contribute to talent identification or 
selection of optimal sports to maximise the talent of specific 
athletes in the future, notwithstanding the serious ethical 
concerns that athletes should have the right to freely select sports 
they want to play regardless of their genes as well as the fact 
that athletic performance is polygenic (no single gene should be 
held accountable for athletic success). For example, Mikami et al 
reported that Japanese sprinters with the RR+RX genotype of 
alpha- actinin-3 (ACTN3) gene had significantly faster personal 
best times for the 100 m than those with XX genotype; however, 
no such association was found in the 400 m sprinters.51 Never-
theless, given the polygenic nature of athletic performance and 
sports skill, talent identification or selection of optimal sports 
by using only limited genetic variants is unlikely to ever be a 
possibility.
Although cardiomyopathies and channelopathies (eg, hyper-
trophic cardiomyopathy, congenital long- QT syndrome)52 are 
usually non- fatal diseases, they are the major causes of sudden 
cardiac death (SCD) in young athletes.53 Most cases of SCD 
in young athletes are probably caused by the combination of 
inherited cardiomyopathy or channelopathy with intensive 
exercise training. Therefore, cardiovascular screening is essen-
tial to prevent SCD in young athletes. Currently, preparticipa-
tion screening of young athletes for prevention of SCD includes 
screening for family history and cardiovascular symptoms, phys-
ical examination, and often a 12- lead ECG, as recommended by 
the European Society of Cardiology.54 Cardiac screening, which 
includes the ECG, has been shown to have a high sensitivity for 
detecting conditions at elevated risk of SCD such as cardiomy-
opathy or channelopathy and has been associated with reduced 
mortality in competitive athletes.55 Nevertheless, accurate diag-
nosis of cardiomyopathy and channelopathy in athletes remains 
a challenge because of the difficulty of distinguishing between 
a so- called athlete’s heart based on physiological adaptation to 
intense training and cardiac diseases.56 However, most cases of 
inherited cardiomyopathy and channelopathy are monogenic 
and numerous causative mutations have been identified for 
each disorder.57–59 Thus, genetic testing may be an important 
tool in the evaluation of athletes with abnormal cardiovascular 
screening, inconclusive cardiac imaging and in athletes with a 
family history of an inheritable cardiac disorder. In the future, 
genetic testing may also have a potential role in cardiac screening.
Identification of genetic variants associated with sport and 
exercise- related traits is of great importance in terms of under-
standing the molecular basis of trainability. For example, defi-
ciency of ACTN3, the most replicated and studied sports 
performance- related gene,60 61 turned out to influence metabolic 
enzyme activity in skeletal muscle and a shift in the proper-
ties of fast fibres towards those characteristics of slow twitch 
fibres.62 These findings are consistent with that the null allele 
of the ACTN3 p.R577X polymorphism (ie, a point mutation 
that usually results in a non- functional protein product) are 
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over- represented in endurance athletes than in power athletes 
in ancestrally diverse populations. Thus, identification of genetic 
variants associated with individual variabilities in sport and 
exercise- related traits could provide novel insights into molec-
ular adaptations in skeletal muscle. Furthermore, integrating 
other ‘omics’ responses to exercise such as transcriptomics and 
proteomics will undoubtedly enhance our understanding of the 
mechanisms of adaptative response to exercise and its individual 
variability.
Weaknesses
Although a large number of studies have been conducted to 
identify sport and exercise- related genes, the findings are mostly 
inconclusive because of a lack of replication. Some studies 
reported completely opposite associations across different popu-
lations (eg, ACE gene).63–65 Sport and exercise- related genes 
and genetic loci confirmed to influence the health status of the 
athlete have not been identified to date mainly due to the lack 
of replication in independent populations. Furthermore, GWAS 
of world class endurance athletes identified no genetic variants 
associated with extreme endurance performance at the genome- 
wide level of significance although several SNP associations 
might be missed in that study because low- density arrays (Illu-
mina Cardio- MetaboChip) were used for genotyping without 
imputation.66 Previous studies teach us that two major problems 
underlie the lack of discovery of novel sport and exercise- related 
genes.
One of the major problems is small sample size. Common 
SNPs associated with polygenic traits (including sport and 
exercise- related traits) generally show modest OR of 1.1–1.567. 
For example, approximately 5500 cases and equal number of 
controls are needed to detect an OR of 1.2 at alpha error of 
5.0×10–8 and power of 80% in a case- control GWAS if minor 
allele frequency is assumed to be 0.3.68 The difficulty of 
recruiting a large number of elite athletes for sufficient power 
explains one of the bottlenecks in the discovery of novel variants 
of small effects associated with athletic performance. Another 
major problem is the deficiency in how the phenotype is being 
assessed. The factors shaping athletic performance are diverse. 
For example, endurance performance that is one of the more 
simple traits in sports, is shaped by VO2max, VO2 at the lactate 
threshold, economy of movement and other parameters.69 
However, each physiological marker of performance is also a 
complex trait, regulated by a network of genes and pathways. 
In most case- control studies of elite athletes, the physiological, 
anthropometric and biomechanical characteristics of the athletes 
are not well phenotyped. Consequently, the definition of ‘elite 
athlete’ in such studies is often ambiguous. The experience of 
participating in a world championship or national competition 
is usually used for defining elite athlete status.70 However, there 
is no biological explanation for clearly distinguishing world class 
athletes from national level athletes. The opportunity and level 
of athletic achievement needed to participate in the Olympics 
or World Championships varies considerably depending on the 
country of origin. This raises the importance of ‘phenomics’, 
which is defined as the acquisition of high- dimensional pheno-
typic data on an organism- wide scale,71 in the field of sport and 
exercise genomics.
Both large sample size and precise phenotyping are necessary 
to reduce the SE and increase statistical power to detect a signif-
icant SNP- trait association. However, it is difficult to perform 
comprehensive and precise phenotyping while keeping adequate 
sample size. For example, The Heritage Family Study, which 
is the only large- scale standardised exercise intervention study 
consisting of well phenotyped participants (n=720) to explore 
genetic variants associated with response to exercise training 
by using Illumina HumanCNV370- Quad v3.0 BeadChips 
(containing approximately 370 000 markers),72 did not yield 
any SNPs associated with VO2max response to exercise training 
at the genome- wide level of significance.73 This study suggests 
that a sample size of less than 1000 is still insufficient despite 
a well standardised intervention protocol and precise pheno-
typing, while the use of a low- density array without imputation 
may also have contributed to the finding of no significant SNP 
associations. The development of technology such as multifac-
eted wearable devices74 is needed for comprehensive and precise 
high- throughput phenotyping of sport and exercise- related 
traits while keeping adequate sample size for genetic associ-
ation analyses. Furthermore, multiple large- scale cohorts with 
well phenotyped participants are needed to replicate and vali-
date the genetic variants detected in a discovery cohort, which 
might require a substantial budget. In the current environment 
of a general ‘research grant famine’, it is often difficult to obtain 
funds in the field of sport and exercise science and medicine to 
perform such large- scale studies compared with medical science 
which directly contribute to health and disease prevention for 
the general population. Financial constraints may also prevent 
the introduction of large- scale genetic approaches into screening 
programmes.75–78 Whether to screen and what precisely the 
preparticipation screening should comprise will be hotly debated 
for years to come, but in the meantime, progress in this field 
would be greatly advanced if in SCD cases in in sport, molecular 
considerations were part of the standardised routine autopsy79 as 
well as the genetic screening of first- degree relatives.80
Understanding the genetic architecture of human athletic 
performance, the widely ranging sport phenotype and other 
sport and exercise- related traits is challenging because of its 
high complexity. Human athletic performance has long been 
assumed to be polygenic except for some rare cases where 
single mutation(s) confers extreme phenotype as in the example 
of a gain- of- function mutation erythropoietin receptor in the 
Olympic cross- country skiing gold medalist.81 An accumulation 
of common variants with small effect size has been suggested to 
explain a large proportion of phenotypic variance of complex 
traits.82 However, to date, only a very small number of common 
variants have been reported to be associated with sport and 
health- related fitness phenotypes.83 Furthermore, recent 
advances in genomics have revealed that an individual carries 
approximately 40 000–200 000 of rare variants (minor allele 
frequency of <0.5%) per individual genome,84 which can help 
explain the phenotypic variance of complex trait,85 justifying 
the necessity to adopt whole genome sequencing technology in 
the field of sport and exercise genomics. In addition to single 
nucleotide variants in the gene regions, other type of genomic 
variation such as structural variation (eg, copy number variation, 
large insertion and deletion),86 variants in non- coding RNA (eg, 
micro RNA, long non- coding RNA)87 may also contribute to 
the complexity of the athletic phenotype. Integration of various 
types of genomic variation by multiomics approach will be 
needed to fully elucidate the complexity of athletic performance.
opportunities
There is considerable commercial opportunity associated with 
the use of genomics in the sport and exercise sciences. A means 
to attract research funding for large- scale sport and exercise 
genomic studies is to collaborate with industry given the recent 
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increase in public interest and use of commercial genetic testing. 
For example, one of the largest DTC genetic testing compa-
nies 23andMe, has collected genetic data from approximately 
5 million consumers. Although the primary service of 23andMe 
is to provide genetic health risks and ancestry information to 
consumers, they also conduct research by using genotype and 
phenotype data obtained from consumers that are collected 
through internet surveys.88 23andMe analyse these data89 and 
also share the data with academic institutions to enhance large- 
scale genetic association studies. Several research groups have 
managed to identify additional loci for various diseases or traits 
using these large datasets.90–92 Furthermore, 23andMe sell their 
data to the pharmaceutical industry for drug development 
research93 as well as support scientists through collaboration 
agreements whereby scientists collect data in the field for analysis 
by 23andMe with the fundamental aim of elucidating a greater 
understanding of the diversity of genomics data globally. In this 
way, scientists and the wider community benefit from this addi-
tional access to grant funding.94 In addition, new research invest-
ments by industry into genomics of sport and exercise has real 
potential to impact the field of genetics of disease with particular 
emphasis on lifestyle- related disorders by helping, for example, 
identify risk factors associated with sedentary lifestyles for wider 
society and public health gain. Such collaborations and commer-
cial partnerships with industry should be pursued, although 
with care. To date, 23andMe is the only personal genomics and 
biotechnology company to offer these opportunities but others 
are expected soon to follow this example given their success.
Threats
Collaboration with industry for genomic research in the sport 
and exercise sciences is not without serious threats. Indus-
tries including DTC genetic testing companies may support 
researchers with the expectation of handing over some of the 
intellectual property that may be generated during the study life 
cycle. Commercial pressure in most cases results in the premature 
exploitation of data that have limited or no scientific bases given 
no or limited replication and validation. For example, DNAFit, 
a DTC genetic testing company active in the UK, has recently 
performed a GWAS of sprint performance in collaboration with 
Russian and Polish scientists, aimed at identifying novel genetic 
markers for their genetic testing product.95 These authors 
reported several SNPs to be associated with sprint performance; 
however, the clinical significance of these results is unknown 
given the small sample size of the discovery cohort and the 
inappropriate replication study (ie, small sample size, different 
outcomes and heterogeneous characteristics of participants 
among the cohorts). Many DTC genetic testing companies have 
already offered genetic testing products for predicting athletic 
performance and talent identification although sport and exer-
cise genomics has provided very limited evidence and predicting 
athletic performance and talent identification by using genetic 
information is almost impossible to this date.96 Some athletes, 
coaches and parents of young individuals may believe the results 
of genetic testing regardless of the accuracy and quality of 
genetic testing products commercially available at present. Use 
of such unproven technology can lead to incorrect decisions such 
as inappropriate early specialisation for sports, inappropriate 
training, genetic discrimination and even increased health risks. 
Genetic testing should therefore be provided with appropriate 
genetic counselling as described in the statement of The Euro-
pean Society of Human Genetics97 and The American Society 
of Human Genetics.98 The vast majority of DTC companies sell 
genetic testing to consumers without providing adequate genetic 
counselling.99 Thus, collaboration with industry has the poten-
tial danger to misuse the data despite the intention of scientists, 
consequently misleading athletes, their coaches and families.
In terms of the privacy and data protection, reidentification 
of anonymised genotype data has become a real concern. For 
example, US law enforcement authorities have begun exploiting 
genetic databases and publicly available family trees to iden-
tify suspects via distant familial relatives and have succeeded 
in arresting numerous suspects.7 This practical use of publicly 
available genetic information for criminal investigation raises 
awareness that reidentification of anonymised genotype data are 
already technically possible. Individual genome information of 
elite athletes must be of special interest to many people. There 
is therefore a possibility that someone may attempt reidentifying 
anonymised genotype data of elite athletes to abuse this data. 
Given the recent rapid development of artificial intelligence, 
reidentification of anonymised genotype data would be much 
easier in the near future. A flow of genetic information from a 
DTC genetic testing company to a third party is another poten-
tial problem in privacy and data protection. DTC genetic testing 
companies provide genetic data to third- party scientists or phar-
maceutical industry for research purposes without consumer’s 
explicit consent. Although several DTC genetic testing compa-
nies obtain additional consent for the secondary use of data, 
the majority of them do not consistently meet international 
transparency guidelines related to privacy and secondary use 
of data.100 Furthermore, the use of third- party interpretation 
services also increases the risk of privacy invasion and misuse of 
data. Consumers can download their raw genetic data from DTC 
genetic testing company website and freely upload it to third- 
party interpretation services for further explanation of genetic 
data. Because the data usage and privacy policy is less prominent 
in the third- party interpretation services than in DTC genetic 
testing companies,101 the risk of data exploitation by someone 
could be high, as US law enforcement authorities have already 
exploited it for criminal investigation.7 Thus, considering the 
feasibility of reidentification of genotype data and unexpected 
use of this, a lack of transparency in the provision of information 
to consumers is a serious problem because it inhibits them from 
recognising the threat of privacy invasion.
Given the development of gene- editing technology such as 
CRISPR/Cas9,102 genetic variants determining athletic perfor-
mance and elite athlete status may be used for gene- doping or 
creating talented sports children in the future. In fact, gene- 
editing of Myostatin in zygotes successfully enhanced muscle 
hypertrophy in several adult mammals.103–105 Even in humans, 
researchers have used gene- editing techniques targeting human 
adult cell for disease therapy18–21 and human germlines.23 24 A 
pertinent recent example is the aforementioned revelations of 
the use of CRISPR/Cas9 gene editing technology to delete both 
copies of the CCR5 gene in embryos to give twin babies resis-
tance to HIV infection in violation of the laws and regulations 
in respective countries. This should not have been performed 
because there is no consensus on how to counsel ‘gene- edited 
individuals’ as well as a limitation in understanding of the long- 
term effects of gene- editing on mature body. In fact, although 
basic research involving gene- editing in human germlines has 
been admitted in several countries (eg, UK, USA, Sweden, 
China and Japan),106–110 human gene- editing for reproduc-
tion is prohibited by law or regulation in many countries.111 
The fact that there are gene- edited babies alive today confirms 
that gene- edited human babies are already technically possible. 
Designing athletes with extraordinary athletic performance by 
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using gene- editing technique would be a real threat in terms of 
keeping sport fair, clean and protecting athlete health.
Guiding reference for sport and exercise genomics
The present SWOT analysis suggests that sport and exercise 
genomics has the potential to contribute to the health and well- 
being of athletes as well as real and necessary advances in the 
field of sport and exercise sciences and medicine. Large- scale 
studies in collaboration with industry may help to provide suffi-
cient scientific evidence to adequately and ethically use genetic 
information of athletes, mainly to protect their health status. 
On the other hand, there are many potential dangers associated 
with the use of genomics in sport and exercise medicine such as 
reidentification of anonymised genotype data, inaccurate genetic 
testing based on insufficient evidence, discrimination and gene 
doping by using novel gene- editing technique. These threats 
must be addressed to protect privacy and health of athletes and 
to keep sports clean.
We therefore propose the following rules of conduct:
All research on sport and exercise genomics should be 
conducted in strict accordance with the local university and any 
associated medical trust ethical guidelines, relevant Data Protec-
tion Acts and EU General Data Protection Regulations (GDPR) 
or similar instruments in other regions of the world. Given the 
transnational nature of genomic work, policies of sponsors and 
partners must also be GDPR compliant.
Scientists must establish strict rules about acquisition of data, 
data flow management, anonymisation, security and data release 
policy before starting the project and collaboration with indus-
tries and other research partners.
Scientists must not receive funds from industries to develop 
the project unless industries completely agree with the scientist’s 
host institute rules based on independent ethical committees and 
are prepared to sign an comprehensive agreement that include 
ethics, data protection, legal safe guards, intellectual property.
Scientists must respect rules regarding the acquisition of 
biological material to prevent exploitation of vulnerable individ-
uals and societies.
Scientists must not receive funds from industries if they aim to 
exploit the data in return for giving funds.
Scientists must not release any data to industries and other 
research groups unless there are strict rules about data flow 
management, anonymisation, security and data release policy. 
Scientists should handle the data to protect individuals from 
privacy invasion and abuse of their personal data.
All experiments and analyses should be performed in house or 
the analysis process and data management are clearly protected 
by rules set out by the service providers and agreed by the 
researchers before commencing the analysis to minimise the risk 
of data leakage, privacy invasion and misuse of personal data.
The IP landscape on CRISPR/Cas9 is complex and constantly 
evolving. Issues surrounding intellectual property rights (IPRs) 
have broad international legal implications; however, for the 
purpose of these guidelines, consideration is given to domestic 
legislation under the Patent Act 1977 (as amended 2005) and the 
European Patent Convention 2000. Legally, IPRs relating to the 
research project belong to the institution of the principal inves-
tigator although the inventor may be entitled to compensation. 
However, a patent holder may infringe their own IPRs where 
rights are transferred to the licensee; therefore, explicit contract 
terms will need to be negotiated ensuring IPRs, where possible, 
remain with the academic institution.
Feedback of genetic data to individuals is not recommended 
unless the accuracy and precision of prediction by genetic infor-
mation is assured by replication and validation studies. Scientists 
must minimise the risk of misinterpretation of genetic informa-
tion by proper genetic counselling if feedback of genetic data is 
required or beneficial for the individuals (eg, incidental findings 
of mutations causing genetic disorders).
Scientists in sport and exercise genomics should perform repli-
cation and validation studies as much as possible to verify the 
results to improve our understanding of the scientific merit of 
the findings.
Scientists should keep enhancing their knowledge of ethics 
and data protection policies pertaining to existing big genome 
projects.
Scientists should try to implement best practice and develop 
a secure encrypted domain to reduce the risk of data leakage.
There should be regular interactions between scientists and 
practicing sports medicine doctors or practitioners to facilitate 
the transfer knowledge of any advancement in the arena for 
example on tools such as gene editing and gene therapy—or any 
other tools to reduce risk and promote the health of the athlete.
Scientists must not use gene editing techniques in somatic 
human cell aimed at enhancing athletic performance. In addi-
tion, scientists must not use gene editing techniques to modify 
DNA in human germlines for creating talented sports children. 
Scientists should keep learning from current guidelines for gene 
editing and gene therapy to establish the regulation to protect 
sports and athletes from threat of gene- doping and creating 
talented sports children.
Sport and exercise genomics is in transition from focused 
research performed by single research groups to large- scale 
discovery research involving many research groups and industry 
partners.29 33 The advancements in sport and exercise genomics 
parallel the increase in the risk of data leakage, privacy inva-
sion and abuse of personal data. At this moment, without strict 
rules about data flow management, anonymisation, security 
and data release policy that is standard practice in the large 
biobank studies,112 113 releasing any genotype and phenotype 
data to industry, other research groups and public databases is 
not recommended. All scientists of sport and exercise genomics 
need to be well- versed in ethics and data protection policy to 
protect individuals from threats of privacy invasion and abuse 
of personal data in preparation for the era of large- scale collab-
orative science.
The application of CRISPR/Cas9 gene editing techniques to 
skeletal muscle as well as hematopoietic stem cells for treatment 
of monogenic diseases is becoming more commonplace.18 21 
Given these rapid advances in gene editing, it is expected and 
totally desirable that these techniques are harnessed by the sports 
medicine physician to treat sports- related injuries. This broader 
application of gene editing techniques to sports medicine will 
inevitably result in gene- doping being a real prospect.114 Knowl-
edge gained from gene- editing research for disease therapy could 
be misused for enhancement of athletic performance. To the best 
of our knowledge, no gene editing techniques have been applied 
in healthy individuals to enhance athletic performance. This 
threat poses new ethical dilemmas and hence the urgent need for 
gene- editing guidelines and regulation constantly updated to deal 
with all eventualities. It is the responsibility of those involved in 
the field of sport and exercise sciences and medicine to keep 
abreast of the gene- editing guidelines.115 It is necessary to prior-
itise research in antidoping with particular reference to gene- 
doping. Although gene doping is already prohibited on the list 
of banned doping agents developed by the World Anti- Doping 
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Agency,116 robust and effective antidoping measures to detect the 
use of gene doping have not been developed. Several PCR- based 
strategies to detect vector- mediated gene transfer of several 
candidate genes (eg, vascular endothelial growth factor, erythro-
poietin, insulin- like growth factors 1, growth hormone) for gene 
doping have been developed.117–119 However, gene transfer of 
unexpected target gene cannot be detected by using these candi-
date gene approaches. Furthermore, the strategy to detect gene 
doping by CRISPR/Cas9 based on DNA modification has not 
been developed so far. Omics technologies have been shown to 
enhance the detection of blood doping,120 121 and these cutting- 
edge technologies could be further harnessed to develop effec-
tive methods for the detection of gene doping in sport. Funding 
institutions should be encouraged to offer grants for further 
developments in the rapidly emerging field of antidoping strat-
egies providing the antidoping laboratories with the tools to 
significantly improve their abilities.
ConCludInG RemARks
The present guidelines in sport and exercise genomics developed 
following an extensive SWOT analysis, advocates the need for 
clear and universal standards as they relate to the collection, 
management and storage of DNA/data with the overriding 
objective to protect individuals from privacy invasion and misuse 
of genomic information. Given the increased availability of high- 
throughput genomic information, there is an urgent need for 
such a guiding reference in sport and exercise genomics with 
a clear and consistent data handling and release policy for all 
individuals who potentially handle any genetic information. It is 
essential that sports physicians, scientists and all those involved 
in supporting the athlete keep abreast with new developments 
in genomics including new technologies and methods such as 
CRISPR/Cas9 and are well informed of the laws and regulations 
pertaining to the collection, storage and use of genetic data. 
Given the rapidly advancing field of sports genomics, regular 
updates to this guiding reference will be needed in order to best 
protect the athletes and all the relevant stakeholders. Conducting 
research in accordance with the present guiding reference will 
reduce the threat brought about by inappropriate use of genomic 
information and allow further development of sport and exer-
cise genomics in accordance with ethical principles.
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